Eli Lilly’s Tough Month: One of The Biggest Global Banks Says 37% Gains Begin Soon
Citigroup's Geoff Meacham targets $1,600 for LLY, representing 37% upside, anchored by Mounjaro and Zepbound's combined $14.9B single-quarter revenue.
Novo Nordisk dropped 8% in one session after its post-Wegovy update disappointed, while Viking Therapeutics carries 207% implied upside on clinical-stage binary risk.
Just released. Our analysts combed the entire stock market and named the ten best stocks to buy right now, and Eli Lilly didn't make the cut. Enter your email to see the names that beat LLY. The report is free. Enter your email and see if any of your stocks made the cut.
Eli Lilly ( NYSE:LLY ) currently trades at $1,164.79, while Wall Street's average analyst price target sits at $1,325.39. That leaves roughly 14% of implied upside between where the stock is and where the consensus says it belongs.
Lilly is the dominant force in the GLP-1 obesity and diabetes market, with Mounjaro and Zepbound now generating a combined $14.9 billion in a single quarter. Wall Street watches this stock closely because it is one of the largest healthcare companies in the world, with a market cap near $1.03 trillion, and because its pipeline may decide whether the entire obesity category becomes a multi-decade franchise.
Lilly just wrapped a rough stretch, and one major bank is arguing the selling is overdone.
Lilly shares have dropped 7.21% over the past month, sliding from about $1,255.40 to current levels even as the broader market pushed higher. Q2 revenue beat consensus by 11.06% and EPS came in 27.27% above estimates.
Pricing anxiety weighed on the stock. Realized U.S. prices fell 9% excluding rebate adjustments, and international pricing compressed after Mounjaro's inclusion in China's National Reimbursement Drug List. Investors also digested $2.78 billion in acquired IPR&D charges and fresh competitive noise from Novo Nordisk's post-Wegovy strategy update on Monday.
24/7 Wall St has helped investors make money for over two decades, and our top analysts just finished ranking the definitive Top 10 Stocks To Buy Now . Not the ten biggest companies. Not the ten everyone is arguing about. The ten best stocks to buy right now.
The report is free, and you can see why we think each stock is a top investment today.
Citigroup's Geoff Meacham carries a Street-high $1,600 price target with a reiterated Buy rating, implying roughly 37% upside from current levels. His model assumes Lilly holds a ~60% commanding global share of the obesity and type 2 diabetes markets, with next-generation assets like oral orforglipron and triple-agonist retatrutide extending the runway well into 2027 and beyond.
Of 30 analysts covering the name, 6 rate it Strong Buy, 18 Buy, 4 Hold, 1 Sell, and 1 Strong Sell. The 2027 EPS consensus climbed from $44.4551 ninety days ago to $47.3443, with 19 upward revisions in the trailing 30 days.
Near-term catalysts include a retatrutide BLA submission targeted for Q1 2027, continued ramp of oral Foundayo, and the Medicare GLP-1 Bridge Program that granted 20 million eligible Americans coverage at $50 per month.
Novo Nordisk ( NYSE:NVO ) closed at $39.81, down 7.93% in a single session after its post-Wegovy strategy update disappointed. With an average target of $46.80, implied upside is about 17.6%. Analysts skew Hold, with 11 Holds against 3 Buys and no Sells.
Viking Therapeutics ( NASDAQ:VKTX ) trades at $30.11 against a consensus target of $92.39, for an implied upside near 207%. That is a clinical-stage biotech skew: 5 Strong Buys, 13 Buys, and 2 Holds. Wall Street is pricing binary trial risk on a clinical-stage biotech.
Pfizer ( NYSE:PFE ) sits at $27.74 versus a $28.88 target, an underwhelming 4.1% of upside. Ratings lean Hold at 16 Holds, 10 Buys, and 2 Sells.
Among cash-generative large-caps, Lilly's 14% consensus gap and Citi's 37% bull case remain the most credible risk-adjusted setup.
Year to date, Lilly is up 8.92%, trailing the S&P 500's 13.43% gain. Over one year, Lilly has returned 55.89% against the SPDR S&P 500 ETF Trust ( NYSEARCA:SPY ) return of 16.54%.
Valuation reflects the growth premium. Lilly trades at a trailing P/E of 39 and a forward P/E of 24, on TTM revenue of $79.67 billion and TTM EPS of $29.75. Consensus sees 2026 EPS of $36.7319 rising to $47.3443 in 2027.
The bull case rests on retatrutide clearing the FDA on schedule, Foundayo maintaining its inflection (management says nearly one out of four new incretin starts are choosing it), and the Medicare Bridge Program expands U.S. access. In that scenario, 2027 EPS above $47 makes today's forward multiple reasonable, and Citi's $1,600 case becomes math rather than hope.
The bear case builds if pricing compresses faster than volume can offset, if retatrutide filing delays push growth into 2028, or if tariffs and payer pressure squeeze margins. Lilly is a premium multiple on premium execution; any crack reprices quickly.
Position sizing should account for volatility. Consensus at $1,325.39 is a reasonable base case; Citi's $1,600 is the reward if the pipeline delivers.
If you have cash sitting in your account right now, give this two minutes. After more than two decades of helping investors beat the market, our top analysts at 24/7 Wall St. put together a definitive report on the Top 10 Stocks To Buy Today. And LLY wasn't one of them.
Contact editorial@247wallst.com for any questions or corrections.
